Differential leukocytes in the lung after intranasal delivery of AdGM-CSF or Addl70-3 (×104/BAL)
| . | Total No. . | MΦ/MO . | PMN . | LC . | EOS . |
|---|---|---|---|---|---|
| Day 2 | 34.1 ± 4.9 (13.4) | 18.1 ± 0.6 (10.5) | 4.9 ± 1.9 (0.9) | 10.9 ± 2.6 (1.4) | 0.04 ± 0.04 (0) |
| Day 4 | 26.3 ± 0.7 (10.1) | 21.3 ± 0.7 (7.6) | 0.7 ± 0.1 (0.7) | 4.1 ± 0.3 (1.7) | 0.13 ± 0.04 (0) |
| Day 7 | 51.9 ± 7.1 (8.4) | 26.9 ± 3.2 (7.5) | 10.8 ± 2.1 (0.08) | 14.2 ± 2.3 (0.7) | 0.16 ± 0.16 (0.05) |
| Day 12 | 88.4 ± 11 (11.7) | 50.4 ± 7.8 (10.8) | 13.2 ± 2.8 (0.17) | 24.0 ± 3.8 (0.64) | 0.76 ± 0.24 (0.03) |
| Day 19 | 22.2 ± 3.3 (10.3) | 18.3 ± 3.1 | 0.38 ± 0.13 (9.6) | 1.94 ± 0.3 (0.2) | 0 (0.5) |
| . | Total No. . | MΦ/MO . | PMN . | LC . | EOS . |
|---|---|---|---|---|---|
| Day 2 | 34.1 ± 4.9 (13.4) | 18.1 ± 0.6 (10.5) | 4.9 ± 1.9 (0.9) | 10.9 ± 2.6 (1.4) | 0.04 ± 0.04 (0) |
| Day 4 | 26.3 ± 0.7 (10.1) | 21.3 ± 0.7 (7.6) | 0.7 ± 0.1 (0.7) | 4.1 ± 0.3 (1.7) | 0.13 ± 0.04 (0) |
| Day 7 | 51.9 ± 7.1 (8.4) | 26.9 ± 3.2 (7.5) | 10.8 ± 2.1 (0.08) | 14.2 ± 2.3 (0.7) | 0.16 ± 0.16 (0.05) |
| Day 12 | 88.4 ± 11 (11.7) | 50.4 ± 7.8 (10.8) | 13.2 ± 2.8 (0.17) | 24.0 ± 3.8 (0.64) | 0.76 ± 0.24 (0.03) |
| Day 19 | 22.2 ± 3.3 (10.3) | 18.3 ± 3.1 | 0.38 ± 0.13 (9.6) | 1.94 ± 0.3 (0.2) | 0 (0.5) |
AdGM-CSF = adenoviral gene vector expressing murine GM-CSF; BAL = bronchoalveolar lavage; GM-CSF = granulocyte-macrophage colony-stimulating factor; EOS = eosinophils; LC = lymphocytes; MΦ/Mo = macrophages/monocytes; PMN = polymorphonuclear neutrophils.
BAL samples were collected at various time points after intranasal delivery of 0.6 × 109 plaque-forming units of AdGM-CSF or Addl70-3. Differential cell types were determined on Diff-Quick stained cytospins. The results for AdGM-CSF treated group are shown and expressed as mean ± SEM from three mice per time point. The results from Addl70-3 control groups are placed in parenthesis and expressed as mean from two mice per time point.